[33] Sacral neuromodulation: Report of initial experience in Kuwait
Objective: To present our 6-year experience with sacral neuromodulation (SNM) since starting implantation in a single centre in Kuwait, as SNM is an established management for several urological and non-urological conditions, and devices and techniques have improved over the past decade. Methods: We...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Taylor & Francis Group
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b4ea1d5ffea74871a2f39894706486f3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Objective: To present our 6-year experience with sacral neuromodulation (SNM) since starting implantation in a single centre in Kuwait, as SNM is an established management for several urological and non-urological conditions, and devices and techniques have improved over the past decade. Methods: We conducted a combined retrospective file review and prospective follow-up of patients who had undergone SNM implants since March 2012 up to May 2018 in Amiri Hospital, Kuwait. We analysed: biometric data; clinical presentation; medical and drug history; surgical history; timeline after the first stage of implantation, including complications and level of satisfaction; and any need for review or explantation of the device. Results: In all, 21 patients underwent SNM implantation between March 2012 and May 2018, 17 (81%) of which were females. The mean age of the patients was 35.9 years, 52.4% had urinary retention, 38.1% had overactive bladder, and 11.8% had dysfunctional voiding. Almost all patients (19) failed or were unsatisfied with prior conservative treatment. Right- and left-sided Stage 1 insertions were of almost equal frequency, and no devices were initially implanted on the contralateral side in the second stage. The mean hospital stay for both stages was just over 1 day postoperatively, and the time between stages was on average 4.4 weeks. Only one patient, who had an unsatisfactory response (<50% resolution of symptoms) after the second stage of implantation, requested explantation. Another patient requested explantation after revision of the procedure failed to improve her symptoms. This patient is one of five who required some form of revision after implantation within a mean of 8.6 months, all but her reporting satisfactory responses. There were no major complications in our series. Conclusion: We report the successful experience of the only unit in Kuwait performing SNM implantation. Our patients report overwhelming satisfactory results both objectively and subjectively. |
|---|